Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States

In 2012, the Food and Drug Administration approved use of bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis (MDR TB). We describe treatment outcomes, safety, and tolerability of bedaquiline in our case series. Data on patients started on bedaquiline for MDR TB...

Celý popis

Podrobná bibliografie

Vydáno v:	Clinical infectious diseases Ročník 71; číslo 4; s. 1010
Hlavní autoři:	Mase, Sundari, Chorba, Terence, Parks, Samuel, Belanger, Ann, Dworkin, Felicia, Seaworth, Barbara, Warkentin, Jon, Barry, Pennan, Shah, Neha
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 14.08.2020
Témata:	Antitubercular Agents - adverse effects Diarylquinolines - adverse effects Humans Retrospective Studies Treatment Outcome Tuberculosis, Multidrug-Resistant - drug therapy United States - epidemiology United States treatment adverse event multidrug-resistant tuberculosis bedaquiline outcome
ISSN:	1537-6591, 1537-6591
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!